Previous 10 | Next 10 |
Common Stock to Begin Trading on a Split-Adjusted Basis upon Market Open on January 4, 2021 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common ...
Can These Biotech Penny Stocks Continue to Climb Amidst a Potential Covid Vaccine? Biotech penny stocks have seen increased popularity in the past few months due to Covid. On Monday, November 9th, Pfizer Inc. ( PFE Stock Report ) announced that its vaccine candidate is more than...
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Acorda Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...
RealNetworks (RNWK) -12% on Q3 earnings release.Aptevo Therapeutics (APVO) -12%.vTv Therapeutics (VTVT) -8% on reporting baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzhe...
Acorda Therapeutics, Inc. (ACOR) Q3 2020 Earnings Conference Call November 3, 2020 16:30 ET Company Participants Tierney Saccavino - Executive Vice President, Corporate Communications Ron Cohen - Founder, Chief Executive Officer & President Conference Call Participants Philip Nadeau - Cow...
Acorda Therapeutics (ACOR): Q3 Non-GAAP EPS of -$0.20 beats by $0.10; GAAP EPS of $0.05 beats by $0.48.Revenue of $53.09M (+11.3% Y/Y) beats by $23.5M.2020 Guidance: Expects AMPYRA net revenue to be $85-$110M, and operating expenses to be $170-$180M.Shares +11.11%.Press Release For fur...
Acorda Therapeutics (ACOR): Q3 Non-GAAP EPS of -$0.23 beats by $0.07; GAAP EPS of $0.05 beats by $0.48.Revenue of $53.09M (+11.3% Y/Y) beats by $23.5M.Shares +11.11%.Press Release For further details see: Acorda Therapeutics EPS beats by $0.07, beats on revenue
INBRIJA ® (levodopa inhalation powder) 3Q 2020 net revenue of $5.8 million; 24% increase over 2Q 2020 AMPYRA ® (dalfampridine) 3Q 2020 net revenue of $27.3 million; 5% increase over Q2 2020 $15 million FAMPYRA ® milestone payment received from Biogen...
5 Penny Stocks To Watch Right Now We’ve got a whole new month and plenty of penny stocks to watch for potential in November. Regardless of where you stand on the matter, you understand that there’s always money to be made with stocks under $5. How you make money is the...
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics Inc. Company Name:
ACOR Stock Symbol:
NASDAQ Market:
Acorda Therapeutics Inc. Website:
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Jo...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...